PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

NCT06652607 · clinicaltrials.gov ↗

RECRUITING

Status

152

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
Metastatic Cancer
Castrate Sensitive Prostate Cancer

Interventions

DRUG: Enzalutamide
DRUG: Apalutamide (Erleada™) 60 mg or 240 mg tablets
DRUG: Darolutamide (Nubeqa®) 300 mg tablets
DRUG: Taxotere (docetaxel)
DRUG: Abiraterone acetate + Prednisone or Prednisolone

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS